Many of these drugs are available, even though not all of them do what is published with no scientific support. Fluconazole is also indicated to decrease the incidence of 200mg fluconazole in patients 200mg fluconazole bone marrow transplantation who receive 200mg fluconazole chemotherapy 200mg fluconazole radiation therapy.

Fluconazole what is See, for example, Robert E. Wittes, "Cancer Weapons, Out of Reach, " Washington Post, June 15, 2004. Daniel Costello, "Setting a price for putting off death: A few more months of life may not be worth the costs of new cancer therapies, some argue." LA Times, March 18, 2007. 13 "Glaxo May Face Resistance To Reimbursement, " November 09, 2006, Dow Jones. Marie McCullough, "A downside to heralded HPV drug: Cost, access, " the Philadelphia Inquirer, January 18, 2007, : philly inquirer health science 20070118 A downside to heralded HPV drug Cost access. html. "The base price - 0 for three shots given over six months - makes it the most expensive of an evergrowing list of childhood vaccines. Private insurance coverage of Gardasil is in flux. Many physicians are complaining about under-reimbursement. And for the uninsured, free or discounted vaccines are very limited for women over 18." Linda A. Johnson for the Associated Press, "Cancer vaccine's price, insurance problems limiting patient access, " Feb. 2, 2007. 14 See cites in fn. 12. Also: James Love, "AstraZeneca tells New Zealand cancer patients they will withdraw cancer drug from the market to protest government pressures to lower prices, " the Huffington Post, December 18, 2005. "Deal reached over cancer drug, " tvnz.co.nz, Dec 19, 2005. Reinhard Angelmar, "NICE or Nasty?, Access and Reimbursement of Multiple Sclerosis Medicines in the UK, " INSEAD Case Study 2006. "Roche: To Appeal UK Nice Tarceva Reimbursement Finding, " Marc 9, 2007, Dow Jones. "The Basel-based pharmaceutical company plans to appeal the U.K. National Institute for Health and Clinical Excellence's, or NICE's, decision not to reimburse patients with lung cancer for Tarceva." Stephen B. Soumerai, "Benefits And Risks Of Increasing Restrictions On Access To Costly Drugs In Medicaid, " Health Affairs, 23, no. 1 2004 ; : 135-146. Lars Rydna, Graham Stokoeb, Gunter Breithardtc, Fred Lindemansd and Adriaan Potgietere, "Patient access to medical technology across Europe: on behalf of Task Force 2 of the Cardiovascular Round Table of the European Society of Cardiology, " European Heart Journal, Volume 25, Number 7, page 611-616. S O Schweitzer, and S R Shiota, "Access and Cost Implications of State Limitations on Medicaid Reimbursement for Pharmaceuticals, " Annual Review of Public Health, Vol. 13: 399-410, May 1992. Generic Fluconazole Considering chart 6 which shows availability of anti-infectives in private pharmacies, the innovator brands of fluconazole and ceftriaxone were more available than the generic versions of the same medicines. Generally, innovator brands were found in similar proportions as the generic versions except for clotrimazole pessaries, ciprofloxacin tablets, and cotrimoxazole suspension of where the generic versions were predominant. Availability of all anti-infectives was greater in private pharmacies than in public facilities. Chart 7: Availability of anti-hypertensives and anti-diabetics in public facilities. Evaluate pupillary response and size. Check for breath odors alcohol or acetone ; . Examine for needle tracks. Examine for Medic-Alert tags.

Fluconazole on line Clinical Research Initiative and Division of Neuroscience and Biomedical Systems C.J.D., J.F.M., J.C.M. ; and Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology G.M. ; , Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, Scotland, and Quintiles Scotland Ltd., Inchwood, Bathgate, Scotland C.M.M. ; Accepted for publication April 14, 1998 This paper is available online at : jpet and galantamine. Novartis pharmaceuticals april 2006 ; , prescribing information , novartis pharmaceuticals, at p3 retrieved on naheed m, green 2001. Lovastatin, simvastatin and atorvastatin are metabolized by the cytochrome P4503A4 pathway and, therefore, levels of these drugs would be significantly affected by the CYP3A4 pathway inhibitors, erythromycin and ketonazole but not by the CYP2C9 pathway inhibitor fluconazole. In addition, as with all statins, simvastatin and atorvastatin are affected by cyclosporine. The pharmacokinetic profiles of simvastatin and atorvastatin differ in the data regarding interactions with fibrates. Simvastatin is affected by gemfibrozil but not by fenofibrate. The data regarding atorvastatin interactions with gemfibrozil or fenofibrate is not available. Fluvastatin is the only statin that has been shown to not be significantly affected by gemfibrozil, but since the drug is metabolized by the CYP2C9 pathway, an inhibitor of this pathway, fluconazole, would be expected to elevate the AUC. The hydrophilic statins, pravastatin and rosuvastatin, are not affected by the CYP3A4 or CYPC29 pathway inhibitors, but are both affected by gemfibrozil and cyclosporine. Table 3 summarizes the drug interaction profile of the various statins and glibenclamide.

Ndc list AMPHETAMINE SALTS 20 MG TAB AMPHETAMINE SALTS 20 MG TAB AMPHETAMINE SALTS 20 MG TAB METOLAZONE 2.5 MG TABLET METOLAZONE 2.5 MG TABLET SYNTHROID 112 MCG TABLET SYNTHROID 112 MCG TABLET SYNTHROID 112 MCG TABLET SYNTHROID 112 MCG TABLET AMMONIUM LACTATE 12% CREAM HUMALOG 100 UNITS ML VIAL SPIRIVA 18 MCG CP-HANDIHALER MAGNESIUM OXIDE 400 MG TAB LOVENOX 80 MG PREFILLED SYRN LOVENOX 80 MG PREFILLED SYRN TRIAMTERENE-HCTZ 37.5-25 CP AVODART 0.5 MG SOFTGEL AVODART 0.5 MG SOFTGEL SPORANOX 100 MG CAPSULE IMITREX 100 MG TABLET METOLAZONE 10 MG TABLET METOLAZONE 10 MG TABLET METOLAZONE 10 MG TABLET PROMETHAZINE 12.5 MG TABLET P-EPHEDRINE-GUAIFEN LA TAB VANIQA 13.9% CREAM INSTA-GLUCOSE 40% GEL DETROL LA 2 MG CAPSULE SA DETROL LA 2 MG CAPSULE FLUOR-I-STRIP AT SOTRET 40 MG CAPSULE FLUCONAZOLE 150 MG TABLET FLUCONAZOLE 150 MG TABLET CIPROFLOXACIN 0.3% EYE DROP CIPROFLOXACIN 0.3% EYE DROP AEROCHAMBER-MASK SMALL MORPHINE SULF 15 MG TAB SA MORPHINE SULF 15 MG TAB SA MORPHINE SULF 15 MG TAB SA MORPHINE SULF 15 MG TAB SA TRIAZ 6% CLEANSER GFN 1, 200 DM 60 TABLET SA GFN 1, 200 DM 60 TABLET SA METHIMAZOLE 10 MG TABLET METHAMPHETAMINE HCL 5 MG TAB DILAUDID 4 MG ML AMPUL GUAIFEN-PHENYLEPHRINE SA TAB GUAIFEN PHENYLEPHRINE SA TAB ADDERALL XR 15 MG CAPSULE SA ADDERALL XR 15 MG CAPSULE SA TRUVADA TABLET ADDERALL XR 30 MG CAPSULE Page 604. 3. Results The microorganisms isolated from the 6714 49% ; positive and uncontaminated samples and their susceptibility to the antimicrobial agents are shown in Tables 13. A total of 2798 strains were isolated. About half of these were E. coli with P. mirabilis, Enterococcus spp. and K. pneumoniae occurring in relatively small numbers. Non-glucose-fermenting Gram-negative bacilli and other enterobacteria made up 24% of isolates; gram-positive cocci, 19% Staphylococcus spp., 10% and Streptococcus spp., 8% ; and yeasts, 8%. The antimicrobial agents with the highest levels of activity against Gram-negative bacilli Table 1 and Fig. 1 ; were amikacin, cefepime and imipenem all of which are restricted to hospital use. Cefuroxime, ciprofloxacin, fosfomycin, gentamicin and nitrofurantoin showed acceptable levels of activity. Seven strains of ESBL-producing E. coli were detected that were resistant to the cephalosporins and aztreonam. Nitrofurantoin was active against all strains of S. aureus Table 2 ; and fluconazole was active against the yeasts isolated Table 3 and glucovance.
02237367 02237368 02237369 ACCURETIC 10 12.5 ACCURETIC 20 12.5 ACCURETIC 20 25 ARICEPT - 5MG TAB ARICEPT - 10MG TAB COGNEX - 10MG CAP COGNEX - 20MG CAP COGNEX - 30MG CAP COGNEX - 40MG CAP 02141442 00891835 02024152 DIFLUCAN - 150MG CAP DIFLUCAN - 2MG ML DIFLUCAN - 10MG ML DIFLUCAN - 40MG ML DIFLUCAN - 50MG TAB DIFLUCAN - 100MG TAB DIFLUCAN - 200MG TAB GLUCOTROL XL - 5MG TAB GLUCOTROL XL - 10MG TAB LIPITOR - 10MG TAB LIPITOR - 20MG TAB LIPITOR - 40MG TAB LIPITOR - 80MG TAB MAXAIR - 0.25MG DOSE MINIPRESS XL - 2.5MG TAB MINIPRESS XL - 5MG TAB NORVASC - 2.5MG TAB NORVASC - 5MG TAB NORVASC - 10MG TAB PLAX PEPPERMINT 20 2 2.5 PLAX REGULAR 20 2 2.5 PLAX SOFT MINT 20 2 2.5 REACTINE - 1MG ML REACTINE - 5MG TAB REACTINE - 10MG TAB REACTINE - 20MG TAB REZULIN - 200MG TAB REZULIN - 300MG TAB REZULIN - 400MG TAB TROVAN - 100MG TAB TROVAN - 200MG TAB TROVAN IV - 5MG ML quinapril hydrochloride hydrochlorothiazide quinapril hydrochloride hydrochlorothiazide quinapril hydrochloride hydrochlorothiazide donepezil hydrochloride donepezil hydrochloride tacrine hydrochloride tacrine hydrochloride tacrine hydrochloride tacrine hydrochloride fluconazole fluconazole fluconazole fluconazole fluconazole fluconazole fluconazole glipizide glipizide atorvastatin calcium atorvastatin calcium atorvastatin calcium atorvastatin calcium pirbuterol acetate prazosin hydrochloride prazosin hydrochloride amlodipine besylate amlodipine besylate amlodipine besylate C09BA C09BA C09BA N06DA N06DA N06DA N06DA N06DA N06DA J02AC J02AC J02AC J02AC J02AC J02AC J02AC A10BB A10BB C10AA C10AA C10AA C10AA R03AC C02CA C02CA C08CA C08CA C08CA tablet tablet tablet tablet tablet capsule capsule capsule capsule capsule injectable solution oral suspension oral suspension tablet tablet tablet sustained-release tablet sustained-release tablet tablet tablet tablet tablet aerosol for inhalation sustained-release tablet sustained-release tablet tablet tablet tablet oral rinse oral rinse oral rinse oral solution tablet tablet tablet tablet tablet tablet tablet tablet injectable solution not sold not sold not sold not sold introduced not sold not sold not sold not sold not sold not sold not sold not sold not sold not sold not sold not sold not sold not sold.
TOBI NEBU TOBRAMYCIN SULFATE SOLN ANTI-MYCOBACTERIALS ANTITUBERCULOSIS ETHAMBUTOL HCL TABS MYAMBUTOL TABS MYCOBUTIN CAPS RIFAMPIN ANTIMALARIAL AGENTS CHLOROQUINE PHOSPHATE TABS DARAPRIM TABS HYDROXYCHLOROQUINE TABS LARIAM TABS MALARONE TABS MEFLOQUINE HCL TABS QUINACRINE HCL POWD QUININE SULFATE ANTHELMINTICS ALBENZA TABS BILTRICIDE TABS MEBENDAZOLE CHEW STROMECTOL TABS ANTIBIOTICS - MISC. AZACTAM SOLR COLISTIMETHATE SODIUM SOLR FUROXONE TABS METRONIDAZOLE 2 PENTAMIDINE ISETHIONATE SOLR PRIMSOL SOLN TRIMETHOPRIM TABS VANCOCIN HCL VANCOMYCIN HCL COLY-MYCIN-M SOLR FLAGYL CAPS FLAGYL TABS FLAGYL ER TBCR KETEK LORABID METRONIDAZOLE 375MG CAPS 2 METRONIDAZOLE 750MG TABS NEBUPENT SOLR PROLOPRIM TABS TINDAMAX1 XIFAXAN CARBAPENEMS INVANZ SOLR MERREM SOLR LINCOSAMIDES OXAZOLIDINONES LEPROSTATICS CLEOCIN SOLN CLEOCIN SUSR CLINDAMYCIN HCL 150CAPS DAPSONE TABS ANTI INFECTIVE COMBO'S MISC. ERYTHROMYCIN SULF SUSR SEPTRA DS TABS SULFAMETHOXAZOLE TRIMETH TRIMETHOPRIM SULFAMETHOXA ANTI - FUNGALS ANTIFUNGALS - ASSORTED ANCOBON CAPS FLUCONAZOLE1 GRIFULVIN GRISEOFULVIN ULTRAMICROSI TABS GRIS-PEG TABS KETOCONAZOLE TABS NYSTATIN VFEND TABS 5 LAMISIL TABS SPORANOX SOLN SPORANOX CAPS DIFLUCAN and inderal.

Author affiliations: department of psychiatric medicine, university of virginia, charlottesville drs johnson and ait-daoud and departments of psychiatry ms akhtar ; and pharmacology dr javors ; , the university of texas health science center at san antonio.

Know which fungicide you took but taking fluconazole requires care if the patient has evidence of renal failure and itraconazole. Steroids: steroids are powerful, potentially toxic drugs that reduce inflammation and suppress the body's immune system, because fluconazole allergy.
Tacrolimus, a therapeutic agent for AD treatment, also has an antifungal effect against approximately half of the Malassezia strains. The immunosuppressive drugs cyclosporine and tacrolimus target calcineurin, and these agents are toxic to Candida albicans and Cryptococcus neoformans 4 ; . In addition, we demonstrated that tacrolimus, with either ITC or KTZ, has synergistic activity against Malassezia. These observations follow earlier reports on a combination of tacrolimus and fluconazole against C. albicans and C. neoformans strains. As immunosuppressive agents cannot be given to patients with deep-seated mycosis immunocompromised hosts ; , the nonimmunosuppressive analog L-685, 818 has been synthesized 5 ; . The combination of topical tacrolimus and an azole agent can simultaneously treat AD and reduce the number of Malassezia cells colonizing the skin surface that are an exacerbating factor. While the synergistic mechanism of the combination of tacrolimus and azole agents is not known, Maesaki et al. 17 ; demonstrated that tacrolimus increases the intracellular concentration of the azole agent in their study of C. albicans. We found no ITC- or KTZ-resistant Malassezia strains. When azole-resistant Malassezia strains colonize the skin, combined treatment with tacrolimus can render them susceptible to azole agents and kamagra.
NEW YORK STATE DEPARTMENT OF HEALTH 09 14 2007 LIST OF MEDICAID REIMBURSABLE DRUGS PRICING ERRORS ARE NOT REIMBURSABLE PRICES EFFECTIVE 09 14 2007 MRA COST -0.58970 8.96120 9.44852 13.91837 -12.14750 4.50290 112.50000 111.56250 -0.43490 0.88250 -0.88250 0.88250 -0.45600 0.45600 COST ALTERNATE -FORMULARY DESCRIPTION ACETATE 0.1 MG TAB FLOVENT HFA 110 MCG INHALER FLOVENT HFA 110 MCG INHALER FLOVENT HFA 220 MCG INHALER FLOVENT HFA 220 MCG INHALER FLOVENT HFA 44 MCG INHALER FLOVENT HFA 44 MCG INHALER FLOVENT 50 MCG DISKUS FLOXIN OTIC SINGLES FLOXIN 0.3% EAR DROPS 0.3% EAR DROPS FLOXIN 300 MG TABLET FLOXURIDINE 500 MG VIAL FLOXURIDINE 500 MG VIAL FLUARIX 2005-06 SYRINGE FLUARIX 2006-07 SYRINGE FLUCONAZOLE POWDER FLUCONAZOLE POWDER FLUCONAZOLE 10 MG ML SUSP FLUCONAZOLE 10 MG ML SUSP 10 MG ML SUSP FLUCONAZOLE 100 MG TABLET FLUCONAZOLE 100 MG TABLET FLUCONAZOLE 100 MG TABLET FLUCONAZOLE 100 MG TABLET FLUCONAZOLE 100 MG TABLET FLUCONAZOLE 100 MG TABLET FLUCONAZOLE 100 MG TABLET FLUCONAZOLE 100 MG TABLET FLUCONAZOLE 100 MG TABLET 100 MG TABLET FLUCONAZOLE 100 MG TABLET FLUCONAZOLE 100 MG TABLET FLUCONAZOLE 100 MG TABLET FLUCONAZOLE 100 MG TABLET FLUCONAZOLE 150 MG TABLET FLUCONAZOLE 150 MG TABLET FLUCONAZOLE 150 MG TABLET FLUCONAZOLE 150 MG TABLET FLUCONAZOLE 150 MG TABLET 150 MG TABLET FLUCONAZOLE 150 MG TABLET FLUCONAZOLE 150 MG TABLET FLUCONAZOLE 150 MG TABLET FLUCONAZOLE 150 MG TABLET PA CD -0 0 0 0 0 -0 A 0 0 0 -0 0 0 0 0 -0 0 0 0 0 -0 0 0 0 0.

Vicks nyquil for children nighttime cold medicine 115 ml $ 29 cad multi-symptom relief of coughs, runny nose, stuffy nose and sneezing and ketoconazole. I made an appt with a psyciatric pharmacologist not just any old psyciatrist aka drug pusher. Conclusions: Patients with IA receiving concomitant LAmB had no observable differences in ANID PK compared with other patients. This is consistent with other screened factors, and consistent with the elimination mechanism of the drug and lamisil.
Two strap front with adjustable velcro r ; closures, stride rite logo detail and easy pull tongue loop.

Codeine Colchicine Contraceptive pill with estrogen progesterone Cycloserine D vitamin ; Danthron Dapsone Dexbrompheniramine maleate with d-isoephedrine Diatrizoate Digoxin Diltiazem Dipyrone Disopyramide Domperidone Dyphylline Enalapril Erythromycin Estradiol Ethambutol Ethanol cf. alcohol ; Ethosuximide Fentanyl Fexofenadine Flecainide Fleroxacin Fluconazole Flufenamic acid Fluorescein Folic acid Gadopentetic Gadolinium ; Gentamicin Gold salts Halothane Hydralazine Hydrochlorothiazide Hydroxychloroquine Ibuprofen Indomethacin Iodides Iodine Iodine povidone-iodine, eg, in a vaginal douche ; Iohexol Iopanoic acid Isoniazid InterferonIvermectin K1 vitamin ; Kanamycin Ketoconazole Ketorolac Labetalol Levonorgestrel Levothyroxine Lidocaine Loperamide Loratadine Magnesium sulfate Medroxyprogesterone Mefenamic acid Meperidine Methadone Methimazole active metabolite of carbimazole ; Methohexital Methyldopa Methyprylon Metoprolol Metrizamide Metrizoate Mexiletine Minoxidil Morphine Moxalactam Nadolol Nalidixic acid Naproxen Nefopam Nifedipine Nitrofurantoin Norethynodrel Norsteroids Noscapine Ofloxacin Oxprenolol Phenylbutazone Phenytoin Piroxicam Prednisolone Prednisone Procainamide Progesterone Propoxyphene Propranolol Propylthiouracil Pseudoephedrine Pyridostigmine Pyrimethamine Quinidine Quinine Riboflavin Rifampin Scopolamine Secobarbital Senna Sotalol Spironolactone Streptomycin Sulbactam Sulfapyridine Sulfisoxazole Sumatriptan Suprofen Terbutaline Terfenadine Tetracycline Theophylline Thiopental Thiouracil Ticarcillin Timolol Tolbutamide Tolmetin Trimethoprim sulfamethoxazole Triprolidine Valproic acid Verapamil Warfarin Zolpidem and lansoprazole and fluconazole. Annual reassessment Replacement of an excipient with a comparable excipient Update of section 4.4 Special warnings and special precautions for use ; of the SPC Summary of Product Characteristics ; concerning the introduction of a statement for use of nevirapine in PostExposure Prophylaxis PEP ; , inclusion of hepatitis B and C as additional risk factors and addition in section 4.8 undesirable effects ; of neutropenia, anaemia and arthralgia as possible sideeffects. The relevant changes have been introduced to the package leaflet. Update of section 5.1 Pharmacodynamic properties ; of the SPC concerning resistance data for perinatal transmission and crossresistance data with efavirenz ; . Update of sections 4.3 Contra-indications ; , 4.4 Special warnings and special precautions for use ; and 4.5 Interaction with other medicinal products and other forms of interaction ; of the SPC referring to the interaction of nevirapine with the protease inhibitors lopinavir and saquinavir, the non-nucleoside reverse transcriptase inhibitor, efavirenz and with St. John's Wort Hypericum perforatum ; . The information available in the SPC in sections 4.4 Special warnings and special precautions for use ; and 5.2 Pharmacokinetic properties ; regarding the effects of hepatic and renal dysfunction on the pharmacokinetic of nevirapine has been updated. Finally, a contra-indication in section 4.3 Contraindications ; and new Special warnings and special precautions for use section 4.4 ; concerning the concomitant use of nevirapine with rifampicin due to the pharmacokinetic interaction of these medicines have been added. Variation to demonstrate compliance with Commission Directive 1999 82 EC and the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Medicinal Products CPMP BWP 1230 98 rev.1 ; . Change in the specification of the active substance. Annual reassessment Changes related to the active substance. Update of the SPC, to add interaction data with fluconazole and warfarin section 4.5 of the SPC ; , and to alter the statement on severe liver impairment in the contra-indication section section 4.3 of the SPC ; . In addition, an update of the SPC on the information related to the occurrence of Stevens-Johnson syndrome in children is proposed section 4.8 of the SPC ; . Update of SPC, to add pharmacodynamic data section 5.1 of the SPC ; : Revision of the wording related to cross-resistance among Non-Nucleoside Reverse Transcriptase Inhibitors NNRTI ; and inclusion of information resulting from the SAINT study on Perinatal Transmission. Renewal Update of the SPC to include the class labelling on Lipodystrophy in sections 4.4 Special warnings and special precautions for use ; and 4.8 Undesirable Effects ; . Relevant changes are equally proposed for the Package Leaflet. Change in the name of a manufacturer of the medicinal product Change s ; to the test method s ; and or specifications for an excipient Change in or addition of manufacturing site s ; for part or all of the manufacturing process Change in test procedure of immediate packaging.
3 Groll AH, Kurz M, Schneider W, Witt V, Schmidt H, Schneider M, Schwabe D: Five-yearsurvey of invasive aspergillosis in a pediatric cancer center. Epidemiology, management and long-term survival. Mycoses 42: 431 442, Ghannoum MA, Rice LB: Antifungal agents: mode of action, mechanism of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12: 501 517, Kontoyiannis DP, Lewis Antifungal drug resistance of pathogenic fungi. Lancet 359: 1135 1144, Sanglard D, Odds FC: Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2: 73 85, Sterling TR, Merz WG: Resistance to amphotericin B: emerging clinical and morphological patterns. Drug Resist Updates 1: 161 165, Mehta RT, Hopfer RL, Gunner LA, Juliano RL, Lopez-Berestein G: Formulation, toxicity, and antifungal activity in-vitro of liposomeencapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother 31: 1897 1900, Wermuth CG: Selective optimization of side activities: Another way of drug discovery. J Med Chem 47: 1 12, Borges-Walmsley MI, Walmsley AR: The structure and function of drug pumps. Trends in Microbiol 9: 71 78, Nakamura K, Niimi M, Niimi K, Holmes AR, Yates JE, Decottignies A, Monk BC, Goffeau A, Cannon RD: Functional expression of Candida albicans efflux pump CDR1p in Saccharomyces cerevisiae strain deficient in membrane transporters Antimicrob Agents Chemother 45: 3366 3374, Albertson GD, Niimi M, Cannon RD, Jenkinson HF: Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 40: 2835 2841, Maesaki S, Marichal P, Hossain MA, Sanglard D, Vanden Bossche H, Kohno S: Synergic effects of tacrolimus and azole antifungal agents against azole-resistant Candida albicans strains. J Antimicrob Chemother 42: 747 753, Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J: Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 39: 2378 2386, Prasad, R., De Wergifosse, P., Goffeau, A., Balzi, E: Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and and levofloxacin.

The drug should also be used with caution in patients with ocular defects e, g.
Cyclosporin : a kinetic study in renal transplant patients found fluconazole 200 mg daily to slowly increase cyclosporin concentrations.
Dosage in patients with impaired renal function fluconazole is cleared primarily by renal excretion as unchanged drug. Co., Inc. USA 3 Baylor College of Medicine, Texas, USA and 4Nara Medical University, Nara, Japan, for example, fluconazole 150mg.